Tocilizumab for Relapsing Polychondritis

McMaster Children's Hospital

Status and phase: Withdrawn; Phase 2

Conditions: Relapsing Polychondritis

Treatments: Drug: Tocilizumab

Study type: Interventional

Funder types: Other

Identifiers

NCT01104480

RP2010

Details and patient eligibility

About

This is a study for one patient with severe relapsing polychondritis which has been unresponsive to other more conventional medications including prednisone, methotrexate, anakinra and TNF inhibitors. Tolerability, and efficacy of the drug, Tocilizumab will be monitored by clinical assessment and bloodwork.

Sex: Male

Ages: 12 to 15 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• A single patient with unremitting inflammatory relapsing polychondritis

Exclusion criteria

• As this is a study in a single patient, there are no exclusions

Trial design

Primary purpose: Treatment

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)